Fluphenazine decanoate
Fluphenazine decanoate structure
|
Common Name | Fluphenazine decanoate | ||
|---|---|---|---|---|
| CAS Number | 5002-47-1 | Molecular Weight | 591.77100 | |
| Density | 1.149 g/cm3 | Boiling Point | 658.1ºCat 760 mmHg | |
| Molecular Formula | C32H44F3N3O2S | Melting Point | 30-32° | |
| MSDS | N/A | Flash Point | 351.8ºC | |
|
Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.
J. Psychosoc. Nurs. Ment. Health Serv. 51(3) , 13-8, (2013) Medication nonadherence has been associated with persistence of psychotic symptoms, relapse, and hospitalization in patients with schizophrenia. Patients with untreated psychosis are significantly less likely to achieve remission, whereas antipsychotic drug a... |
|
|
Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
Int. Clin. Psychopharmacol. 28(5) , 261-6, (2013) Long-term follow-up data of patients with schizophrenia on depot antipsychotics have been few and the longest follow-up period has been up to 7 years. We carried out a systematic chart review to examine 10-year outcomes for outpatients with schizophrenia who ... |
|
|
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.
Am. J. Addict. 15(2) , 166-73, (2006) This retrospective study of patients treated in a ninety-day, inpatient, dual-diagnosis treatment program examined antipsychotic effectiveness in this population using length of stay in treatment and successful program completion as outcome measures. All pati... |
|
|
Risks versus benefits of different types of long-acting injectable antipsychotics.
J. Clin. Psychiatry 67 Suppl 5 , 15-8, (2006) Since their introduction into clinical practice in the early 1960s, long-acting depot antipsychotics have been widely used as maintenance therapy for patients with schizophrenia. The improved pharmacokinetics of injectable long-acting antipsychotic therapies ... |
|
|
Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.
Psychiatr. Serv. 58(4) , 482-8, (2007) Investigators compared patient characteristics and antipsychotic use patterns between individuals with schizophrenia treated in usual care with first-generation depot antipsychotics and those treated with oral antipsychotics (first- or second-generation or bo... |
|
|
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Schizophr. Res. 119(1-3) , 153-9, (2010) This study aimed to characterize the inpatient utilization of depot antipsychotics.The characteristics of adults with schizophrenia or schizoaffective disorder, hospitalized for at least 28 days, and who were prescribed depot antipsychotics were examined from... |
|
|
Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy.
Vojnosanit. Pregl. 70(3) , 267-73, (2013) There is a high rate of schizophrenic patients who do not adhere to their prescribed therapy, despite the implementation of antipsychotic long-acting injections and the introduction of atypical antipsychotics. The aim of this study was to investigate the diff... |
|
|
The challenge of patients with severe psychiatric illness who do not access care - a way forward.
Trop. Doct. 40(4) , 247-8, (2010) Psychiatric illnesses are a significant cause of morbidity all over the world. In India many people with mental disorders are unable to access psychiatric care for a variety of reasons. This article describes the successful management of a person with schizop... |
|
|
Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome.
Gen. Hosp. Psychiatry 33(1) , 84.e5-7, (2011) We present the case of a woman with paranoid schizophrenia who was receiving oral risperidone. She developed neuroleptic malignant syndrome (NMS) following the addition of depot fluphenazine for the treatment of refractory delusions. NMS subsided and psychoti... |
|
|
Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.
Schizophr. Res. 53(1-2) , 25-30, (2002) Finding a dose of an antipsychotic for maintenance therapy that is both safe and effective can be difficult because clinicians are unable to titrate dose against clinical response in patients who are already stable. Therapeutic monitoring of antipsychotic pla... |